

2 January 2025

Privatisation by way of merger

Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc.

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description of relevant securities	Description of products	Nature of dealings	Number of reference securities to which the derivatives relate	Maturity date / closing out date	Reference price	Total amount paid / received	Resultant balance (including those of any person with whom there is an agreement or understanding)
CICC Financial Trading Limited	31 December 2024	Derivatives	Other types of products	Closing out of a derivative contract	46,700	25 January 2025	\$23.7611	\$1,109,644.0300	194,100
		Derivatives	Other types of products	Closing out of a derivative contract	2,300	17 April 2025	\$23.7469	\$54,617.9100	194,100
		Derivatives	Other types of products	Closing out of a derivative contract	44,400	17 April 2025	\$23.7970	\$1,056,587.2500	194,100

End



Note:

CICC Financial Trading Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

CICC Financial Trading Limited is ultimately owned by China International Capital Corporation Limited.